P450-BM3 Variant Engineering for Broad Substrate Oxidation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for P450-BM3 enzymes that exhibit high levels of enzymatic activity over a wide range of substrates, as existing P450-BM3 enzymes are limited in their substrate versatility.
Innovation Solution
Development of recombinant P450-BM3 variants with improved activity, including specific sequences and variants that exhibit at least 70-99% sequence identity to SEQ ID NO:4-68, and enhanced catalytic performance on substrates such as diclofenac, para-nitroanisol, verapamil, and nifedipine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If wild-type P450-BM3 enzyme is used, then the enzyme structure is simple and easy to produce, but the substrate versatility and catalytic activity are limited
Solution Approach 1:
The patent applies parameter changes by systematically varying amino acid sequences at specific positions in the P450-BM3 enzyme to enhance substrate versatility. Multiple variants with different sequence identities (70-99%) are created through controlled modifications, allowing the enzyme to accommodate diverse substrates while maintaining catalytic function
Solution Approach 2:
The patent creates universal P450-BM3 variants capable of oxidizing multiple substrate types including nifedipine, propranolol, verapamil, diclofenac, and para-nitroanisol. The engineered enzyme performs multiple catalytic functions across different substrate classes, achieving multi-functionality through sequence optimization
2Productivity
If wild-type P450-BM3 enzyme is used, then the production process is simple, but the catalytic activity and enzymatic efficiency are insufficient
Solution Approach 1:
The patent improves catalytic activity by changing amino acid parameters at key positions in the enzyme sequence. Variants with 70-99% sequence identity to SEQ ID NO:4-68 are designed to enhance turnover numbers and reaction rates, achieving up to 200-fold improvement in catalytic efficiency
Solution Approach 2:
The patent uses recombinant DNA technology to copy and replicate optimized P450-BM3 sequences in host organisms. The engineered sequences are synthesized and expressed in bacterial or eukaryotic systems, enabling scalable production of high-activity enzyme variants
3Productivity
If P450-BM3 variants with high sequence identity are created, then the catalytic activity is improved, but the sequence complexity increases
Solution Approach 1:
The patent precisely controls sequence identity parameters by creating variants with defined similarity levels (70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to reference sequences). This systematic parameter control enables optimization of both activity and manufacturability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The improved P450-BM3 variants demonstrate increased enzymatic activity, with up to 200-fold improvement in catalytic activity compared to wild-type enzymes, facilitating efficient oxidation of multiple organic substrates.
Implementation Method 1
P450-BM3 is unique, in that the reductase (65 kDa) and monooxygenase (55 kDa) domains of the enzyme are fused and produced as a catalytically self-sufficient 120 kDa enzyme. The P450-BM3 variants oxidize at least three organic substrates.
Data Source
AI summary
The present invention provides improved P450-BM3 variants with improved activity. In some embodiments. the P450-BM3 variants exhibit improved activity over a wide range of substrates.